Please ensure Javascript is enabled for purposes of website accessibility
Maxx Chatsko

Maxx Chatsko

XMFBlacknGoldX

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

254 binoculars

What Investors Need to Watch When Albemarle Reports Q1 Earnings

All three of the company's business segments are under pressure during the coronavirus pandemic.


353 doctor boxing gloves

Catalent Expects to Finish Fiscal 2020 Strong Amid Coronavirus Pandemic

It helps that the current fiscal year concludes at the end of June, but the business also remains an essential partner for the pharmaceutical industry.


220 paper inventory

WestRock Cuts Dividend to Protect Balance Sheet During Pandemic

The paper engineering leader announced a range of steps to preserve its financial position and prioritize debt reduction.


492 arrow against the pack

Will Clinical Trial Delays Derail Repligen's Growth?

The bioprocess leader relies on clinical trials for a significant portion of revenue. How disruptive will the coronavirus be?


telemedicine

The Coronavirus Pandemic Will Test Invitae's Telemedicine Ambitions

Invitae wants to provide medical-grade genetic testing to the masses. Is the business ready for the first big test?

multiple lines down

Here's Why Athersys Tumbled 23.3% in April

The stem cell stock has delivered a 100% gain since the beginning of the year. Can it hold?


589 question mark cards

1 Question to Ask Yourself Before Buying Renewable Energy Group

Petroleum markets are in disarray, but the renewable fuels stock has lost comparatively little ground. What's going on?


chalkboard stock down pink

Here's Why BioNTech Lost 18.7% in April

Shares simply cooled off from an impressive run-up through March, but investors are still closely watching this biotech stock.


multiple lines down

Here's Why NeoGenomics Is Tumbling Today

The company decided to pull the trigger on a combined offering of stock and debt to pad its balance sheet during uncertain times.


600 businessman winning

Will Tandem Diabetes Care Experience a COVID-19 Slowdown?

Investors might consider the company's products to be essential, but the business could face temporary problems getting products into the hands of new customers.

534 question cards wooden box

Is Fate Therapeutics a Buy?

The cell therapy pioneer has a promising early-stage pipeline and just landed a huge partner. What should investors make of this high-risk, high-reward stock?


046 dna model

NeoGenomics Prioritizes the Public Good During COVID-19 Slowdown

Despite experiencing a double-digit decline in test volumes, the cancer genetics lab hasn't furloughed employees. It has even retooled labs to process COVID-19 swab and blood tests.


scientist dejected

Blueprint Medicines Tumbles 20.8% on Phase 3 Study Failure

A closely watched drug candidate didn't meet the primary endpoint of a late-stage trial, which creates a wide-open opportunity for a competitor.


557 doctor visit

Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?

Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.


stock down erased chalkboard

Shares of Mesoblast Tumbled Over 20% Today After Doubling Last Week

The Australian stem-cell therapy developer presented promising data for COVID-19 patients days ago, but investors took some gains off the table today.

business growth

Here's Why Invitae Stock Popped as Much as 13.2% Today

A rising tide lifts all ships.


410 binoculars kid

The Most Important Thing to Watch When NeoGenomics Reports Earnings

Test volumes fell by double digits at the end of March compared with the year-ago period. How long does management think that trend will continue?


multiple lines up

Here's Why Pluristem Therapeutics Jumped Over 28% Today

The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.


arrow up shelves

Mesoblast Soars 219% on Promising COVID-19 Clinical Trial Data

The small-scale study, including just 12 patients, could signal big potential for the stem cell company's drug candidate.


066 collaboration software getty

2 Top Growth Stocks to Buy Right Now

These two stocks should be relatively insulated from the economic downturn just over the horizon.